{"id":"hepcortespenlisimut-l","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By increasing hepcidin levels, hepcortespenlisimut-L aims to reduce iron overload in the body, which can be beneficial for patients with conditions such as hemochromatosis. This mechanism is distinct from traditional iron chelation therapies, which remove excess iron from the body. Instead, hepcortespenlisimut-L promotes the body's natural iron regulation processes.","oneSentence":"Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:06.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of iron overload in patients with beta-thalassemia major"}]},"trialDetails":[{"nctId":"NCT02256514","phase":"PHASE2","title":"Open Label Trial of Immunotherapy for Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Immunitor LLC","startDate":"2014-09","conditions":"HCC, Liver Cirrhosis","enrollment":120},{"nctId":"NCT02232490","phase":"PHASE3","title":"Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L","status":"UNKNOWN","sponsor":"Immunitor LLC","startDate":"2015-01","conditions":"Hepatocellular Carcinoma, HCC, Liver Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["V5"],"phase":"phase_3","status":"active","brandName":"hepcortespenlisimut-L","genericName":"hepcortespenlisimut-L","companyName":"Immunitor LLC","companyId":"immunitor-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism. Used for Treatment of iron overload in patients with beta-thalassemia major.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}